Tuesday, August 12, 2014

Exact Sciences Corporation EXAS 17.46 Share NASDAQ

Exact Sciences Corporation (Madison Wisconsin) NASDAQ symbol EXAS is trading about 17.46 per share.  Net income and slender profit margins aside the FDA approval of Cologuard is a solid boost for perceptions related to return on equity. 

Cologuard is a non invasive colon cancer detection test.  The test identifies hemoglobin, and certain DNA abnormalities related to a diagnosis of colorectal cancer.  This gives health care insurance plans an opportunity to facilitate clinical access to another option to screen for colorectal cancer.

Cologuard can be ordered post medical doctor visit for about 599.00 per kit.  Exact Sciences will be actively seeking contracts with health insurance plans who will deliver rapid access to large populations of individuals over 50 and considered at risk for colorectal cancer.

Cologuard consultants will be educating medical providers on the benefits of this type of test.  The focus will be to strengthen the perceptions as a primary diagnostic tool in the process of identifying the colorectal disease process.  At home process may trump outpatient visit which would increase EXAS share value. 

Home Care Path celebrates 4 years of successfully serving seniors in South Central Wisconsin

 
 

 App  http://appsmakerstore.com/appim/j6kcdet8xvwk4s


Blog  http://homecarepathseniorcare.blogspot.com/

 Home Care Path  www.homecarepath.com and the Wisconsin PATH ALONG model deliver an advanced supportive care service.  Helping seniors in the home, with clinic visits, at the hospital, nursing home and assisted living facility.  Helping seniors downsize with a move in to an adult child's home. 2014 rates are 20.00 per hour.  Simply call 608-432-4286 to schedule an interview.  We can be there when you are working.  We accept long term care insurance.  Services can be tax deductible.  Help with resources and the transition from private payment to public funded programming.  Valuing home and human life

No comments:

Post a Comment